title: Berberine ameliorates nonbacterial prostatitis via multi-target metabolic network regulation.
abstract: Metabolomics has been increasingly applied to discovering biomarkers and identifying perturbed pathways. Berberine has been shown to exhibit anti-inflammatory, antioxidant, and anticancer properties, but its mechanisms for treating nonbacterial prostatitis (NBP) remain unclear completely. We developed the untargeted metabolomics approach based on UPLC-Q-TOF-HDMS to profile the metabolite changes in urine samples in order to discover novel potential biomarkers to clarify mechanisms of berberine in treating a rat model of capsaicin-induced nonbacterial prostatitis (NBP). The changes in metabolic profiling were restored to their base-line values after berberine treatment according to the principal component analysis (PCA) score plots. Fourteen different potential biomarkers and five acutely perturbed metabolic pathways contributing to the treatment of NBP were discovered and identified. Specifically, the berberine-treated rats are located closer to the normal group, indicating that the NBP-induced disturbances to the metabolic profile were partially reversed by berberine treatment. After treatment with berberine, the relative contents of 12 potential biomarkers were effectively regulated, which suggested that the therapeutic effects of berberine on NBP may involve regulating disturbances to the metabolism. Our results show that the protective effect of berberine occurs in part through a reversal of the NBP-caused disturbances.
authors.affiliation: National TCM Key Laboratory of Serum Pharmacochemistry, Laboratory of Metabolomics and Chinmedomics, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine , Harbin, China .
authors.forename: Hui
authors.initials: H
authors.lastname: Sun
authors.forename: Huiyu
authors.initials: H
authors.lastname: Wang
authors.forename: Aihua
authors.initials: A
authors.lastname: Zhang
authors.forename: Guangli
authors.initials: G
authors.lastname: Yan
authors.forename: Yue
authors.initials: Y
authors.lastname: Zhang
authors.forename: Na
authors.initials: N
authors.lastname: An
authors.forename: Xijun
authors.initials: X
authors.lastname: Wang
mesh_terms: D000818:Animals; D001599:Berberine / Q000494:pharmacology* / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D001706:Biopsy; D001798:Blood Proteins / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D008297:Male; D053858:Metabolic Networks and Pathways / Q000187:drug effects*; D055442:Metabolome; D055432:Metabolomics / Q000379:methods; D011472:Prostatitis / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D051381:Rats
chemical_list: D015415:Biomarkers; D001798:Blood Proteins; D016207:Cytokines; D018836:Inflammation Mediators; D001599:Berberine